



12-05-01

0320
PATENT BOX 562
674528-2003.1 #1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Abulajadel
Serial No. : 09/853,188
Filed : May 9, 2001
For : A DEVICE
Art Unit : To Be Assigned
Examiner : To Be Assigned

745 Fifth Avenue
New York, NY 10151


EXPRESS MAIL

Mailing Label Number: EV 001418513 US

Date of Deposit: November 2, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents and Trademarks, Washington, DC 20231.


(Typed or printed name of person mailing paper or fee)


(Signature of person mailing paper or fee)

AMENDMENT IN RESPONSE TO NOTICE TO COMPLY
WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Commissioner for Patents
Box Sequence
Washington, D.C. 20231

Dear Sir:

This is in response to the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence mailed on November 5, 2001 setting a two-month term for reply. As this response is being submitted before the end of the term for reply, it is believed that no fees are necessary, however, the Commissioner is authorized to charge any fees, or credit any overpayments, to Deposit Account 50-0320. Applicants

respectfully request acceptance of the enclosed paper copy and computer readable form of the Sequence Listing. It is also respectfully requested that the application be amended as follows:

IN THE SPECIFICATION:

Page 67, lines 8-9, please rewrite the paragraph thereat as follows:

- JHFa AAA GGT GCT GGG GGT CCC CTG (SEQ ID NO: 1)
JHFb CCC AGT GCT GGA AGT ATT CAG C (SEQ ID NO: 2)

Page 67, lines 13-14, please rewrite the paragraph thereat as follows:

- JH6a CAT TGT GAT TAC TAC TAC TAC TAC (SEQ ID NO: 3)
JH6b GAT CCT CAA GGC ACC CCA GTG C (SEQ ID NO: 4)

Page 67, lines 18-19, please rewrite the paragraph thereat as follows:

- Beta ACT-1 AAG GCC AAC CGC GAG AAG AT (SEQ ID NO: 5)
Beta ACT-2 TCG GTG AGG ATC TTC ATG AG (SEQ ID NO: 6)

Immediately after page 128 and before the first page of claims (page 129), please insert the enclosed pages identified as --Sequence Listing--.

REMARKS

It is respectfully asserted that the sequence disclosure contained in the application now fully complies with the requirements set forth in 37 C.F.R. § 1.821 to § 1.825. Accordingly, reconsideration and withdrawal of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (“Notice to Comply”) is respectfully requested.

A copy of the Notice to Comply, a paper-copy of the Sequence Listing, and a computer readable form (floppy disk) of the Sequence Listing are enclosed. It is respectfully submitted that the Sequence Listing conforms to the requirements of 37 C.F.R. §1.823(b). The Statements required by 37 C.F.R §1.821(f) and (g) are set forth below.

Pursuant to 37 C.F.R. §1.821 (g), the undersigned attorney of record hereby states that this submission, filed in accordance with 37 C.F.R. §1.821 (g), does not contain new matter.

Pursuant to 37 C.F.R. §1.821 (f), the undersigned attorney hereby states that the content of the paper and computer readable copies of the Sequence Listing submitted in accordance with 37 C.F.R. §1.821 (c) and (e), respectively, are the same.


CONCLUSION

In view of the amendments, remarks and enclosures herein, it is respectfully submitted that the application now complies with the requirements for computer readable disclosure of the biological sequences under 37 C.F.R. §1.821-1.825. Reconsideration and withdrawal of the Notice to Comply is earnestly solicited.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP
Attorneys for the Applicant

By:


Thomas J. Kowalski
Reg. No. 32,147
(212) 588-0800

Enclosures: Paper and Diskette copies of Sequence Listing
Copy of Notice to Comply
Return receipt postcard

"VERSION WITH MARKINGS TO SHOW CHANGES MADE"

Page 67, lines 8-9:

JHFa AAA GGT GCT GGG GGT CCC CTG (SEQ ID NO: 1)

JHFb CCC AGT GCT GGA AGT ATT CAG C (SEQ ID NO: 2)

Page 67, lines 13-14,:

JH6a CAT TGT GAT TAC TAC TAC TAC TAC (SEQ ID NO: 3)


JH6b GAT CCT CAA GGC ACC CCA GTG C (SEQ ID NO: 4)

Page 67, lines 18-19:

Beta ACT-1 AAG GCC AAC CGC GAG AAG AT (SEQ ID NO: 5)

Beta ACT-2 TCG GTG AGG ATC TTC ATG AG (SEQ ID NO: 6)

8



SEQUENCE LISTING

<110> Abulayjadayel, Ilham Mohamed Saleh Saeed

<120> A Device

<130> 674528-2003.1

<140> 09/853,188

<141> 2001-05-09

<160> 6

<170> PatentIn version 3.0

<210> 1

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer JHF_a, designed to amplify a 240 bp fragment of the IgH JHF gene

<400> 1

aaaggtgctg ggggtccccc t g

21

<210> 2

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer JHF_b, designed to amplify a 240 bp fragment of the IgH JHF gene

<400> 2

cccagtgc tg gaagtattca gc

22

<210> 3

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer JH6_a, designed to amplify a 242 bp fragment of the IgH JHF gene joining region 6

<400> 3

catttgattt actactacta ctac

24

<210> 4

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer JH6b, designed to amplify a 242 bp fragment of the IgH JHF gene joining region 6

<400> 4

gatcctcaag gcaccccaagt gc

22

<210> 5

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer Beta-ACT-1, designed to amplify a 249 bp fragment of the B-actin gene

<400> 5

aaggccaacc gcgagaagat

20

<210> 6

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer Beta-ACT-2, designed to amplify a 249 bp fragment of the B-actin gene

<400> 6

tccgtgagga tcttcatgag

20